Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19

Dr Frederick Chen - Barts Health NHS Trust, London, UK
Romiplostim thrombopoietin receptor agonist rapidly restores platelet counts in acute ITP in 1L treatment during COVID 19 ( Dr Frederick Chen - Barts Health NHS Trust, London, UK )
18 Jun 2026

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy
Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma ( Prof Umberto Vitolo - Oncological Institute Candiolo, Turin, Italy )
18 Jun 2026

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC ( Dr Bjorn Henning Gronberg - Norwegian University of Science and Technology, Trondheim, Norway )
10 Jun 2026

ASCO 2026: Lung cancer roundup

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
ASCO 2026: Lung cancer roundup ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
3 Jun 2026

Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC

Dr Kevin Kalinsky - Winship Cancer Institute, Atlanta, USA
Sacituzumab govitecan plus pembrolizumab improves outcomes beyond progression in PD-L1-positive mTNBC ( Dr Kevin Kalinsky - Winship Cancer Institute, Atlanta, USA )
2 Jun 2026

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia
Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma ( Dr Matteo S. Carlino - Westmead Hospital and Melanoma Institute Australia, Sydney, Australia )
1 Jun 2026

Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups

Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA
Tarlatamab in SCLC shows consistent effect and low immune toxicity across age groups ( Dr Raymart Macasaet - Monmouth Medical Center, Long Branch, USA )
1 Jun 2026

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA
Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma ( Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA )
1 Jun 2026

Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer

Dr Vincent Chung - City of Hope, Duarte, USA
Olaparib plus pembrolizumab improves response but not PFS in BRCA-mutant pancreatic cancer ( Dr Vincent Chung - City of Hope, Duarte, USA )
1 Jun 2026

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA
Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2026

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke
ASCO 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke )
30 May 2026